Category | Preferred term | Number (%) of patients reporting AEs | Number of TEAEs grade ≥ 3 (all dosing groups) | |||
---|---|---|---|---|---|---|
Dose assigned (vp) | ||||||
< 1 × 1012 vp (n = 6) | 1–3 × 1012 vp (n = 26) | > 3 × 1012 vp (n = 29) | All dosing groups (N = 61) | |||
Any TEAE | 6 (100) [4] | 26 (100) [25] | 29 (100) [29] | 61 (100) [58] | 161 [90] | |
Any SAE | 1 (16.7) | 7 (26.9) [4] | 12 (41.4) [6] | 20 (32.8) [10] | ||
TEAEs of interestb | ||||||
Influenza-like symptoms | Chills, n (%) | 0 | 18 (69.2) [18] | 23 (79.3) [23] | 41 (67.2) [41] | 0 |
Influenza-like illness, n (%) | 0 | 7 (26.9) [7] | 6 (20.7) [6] | 13 (21.3) [13] | 0 | |
Pyrexia, n (%) | 2 (33.3) [1] | 20 (76.9) [19] | 23 (79.3) [23] | 45 (73.8) [43] | 2 [2] | |
Acute respiratory symptoms | Acute lung injury, n (%) | 0 | 0 | 1 (3.4) [1] | 1 (1.6) [1] | 1 [1] |
Dyspnea, n (%) | 1 (16.7) | 6 (23.1) [2] | 7 (24.1) [3] | 14 (23.0) [5] | 3 [2] | |
Hypoxia, n (%) | 0 | 1 (3.8) [1] | 5 (17.2) [5] | 6 (9.8) [6] | 9 [9] | |
Interstitial lung disease, n (%) | 0 | 0 | 1 (3.4) [1] | 1 (1.6) [1] | 1 [1] | |
Renal events | Acute kidney injury, n (%) | 0 | 1 (3.8) | 3 (10.3) [2] | 4 (6.6) [2] | 1 |
Blood creatinine increased, n (%) | 0 | 0 | 2 (6.9) [1] | 2 (3.3) [1] | 0 | |
Glomerulonephritis membranoproliferative, n (%) | 0 | 0 | 1 (3.4) [1] | 1 (1.6) [1] | 0 | |
Nephrotic syndrome, n (%) | 0 | 1 (3.8) [1] | 0 | 1 (1.6) [1] | 1 [1] | |
Proteinuria, n (%) | 0 | 5 (19.2) [4] | 5 (17.2) [5] | 10 (16.4) [9] | 1 [1] | |
Renal failure, n (%) | 0 | 0 | 1 (3.4) [1] | 1 (1.6) [1] | 0 | |
Hepatic events | ALT increased, n (%) | 1 (16.7) | 1 (3.8) [1] | 12 (41.4) [11] | 14 (23.0) [12] | 4 [4] |
AST increased, n (%) | 2 (33.3) | 2 (7.7) [1] | 10 (34.5) [9] | 14 (23.0) [10] | 5 [4] | |
Transaminases increased, n (%) | 0 | 2 (7.7) [2] | 2 (6.9) [2] | 4 (6.6) [4] | 1 [1] | |
Coagulation disorders | aPTT, n (%) | 0 | 2 (7.7) [2] | 5 (17.2) [4] | 7 (11.5) [6] | 1 [1] |
Fibrin D-dimer increased, n (%) | 0 | 5 (19.2) [4] | 9 (31.0) [8] | 14 (23.0) [12] | 5 [4] | |
International normalized ratio increased, n (%) | 1 (16.7) | 1 (3.8) [1] | 3 (10.3) [2] | 5 (8.2) [3] | 0 | |
Hematological events | Anemia, n (%) | 1 (16.7) | 6 (23.1) [2] | 9 (31.0) [2] | 16 (26.2) [4] | 5 [1] |
Leukopenia/WBC count decreased, n (%) | 0 | 3 (11.5) [3] | 0 | 3 (4.9) [3] | 0 | |
Lymphopenia/lymphocyte count decreased, n (%) | 0 | 4 (15.4) [4] | 2 (6.9) [2] | 6 (9.8) [6] | 8 [7] | |
Neutropenia/neutrophil count decreased, n (%) | 0 | 2 (7.7) [2] | 5 (17.2) [5] | 7 (11.5) [7] | 7 [7] | |
Thrombocytopenia/ platelet count decreased, n (%) | 1 (16.7) [1] | 5 (19.2) [5] | 13 (44.8) [13] | 19 (31.1) [19] | 4 [4] | |
Any TEAE relating to WBC count, n (%) | 0 | 6 (23.1) [6] | 6 (20.7) [6] | 12 (19.7) [12] | 0 |